Change in Preferred Drug List Status for the Macrolides-Ketolides Drug Class

In response to the preferred brand name product Eryped 200 MG/5 ML suspension shortage, HHSC removed the non-preferred status from the generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension on the preferred drug list. The preferred status of the brand name Eryped 200 MG/5 ML suspension will not change to allow for any existing stock available to be utilized. These changes will allow providers to prescribe the generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension without requiring a PDL prior authorization and continue accessing necessary medication for clients.

Other News

• Policy Regarding Health Benefit Plan Coverage Of Prescription Contraceptive Drugs Finalized, Implements January 2024
• HHSC publishes the Annual Performance Report for the Prescription Drug Rebate Program Report
• Quarterly Clinical Prior Authorization Assistance Chart Now Available

Reminders

• Pharmacy Education Information and Opportunities
• Pharmacy Email Addresses Must Be Current in PEMS